Page 6 - தேசிய மருத்துவ மேலாண்மை ப்ரோடொகால் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

People s Sufferings Amid Covid Not Taken Lightly : Centre In Supreme Court

People s Sufferings Amid Covid Not Taken Lightly : Centre In Supreme Court
ndtv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ndtv.com Daily Mail and Mail on Sunday newspapers.

National vaccine strategyCentre onSupreme courtNational clinical management protocolCentral drugs laboratorySerum institute of indiaCentral drugs standard control organisationSufferings amid covidNot taken lightlyCentre tells supreme courtCentral governmentState governmentsSerum instituteBharat biotechதேசிய தடுப்பூசி மூலோபாயம்மையம் ஆன்

Remdesivir not magic bullet, does not reduce mortality, says AIIMS chief

Amid a steep spike in COVID-19 cases leading to increased demand for medicines for treating coronavirus, top health experts in the government on Monday said anti-viral drug remdesivir is not a magic bullet and does not reduce mortality. Addressing the media, AIIMS Director Dr Randeep Guleria said remdesivir should only be given to patients hospitalised with moderate illness, who had a fall in oxygen saturation and have infiltrates on chest X-rays or CT-scan. Remdesivir is not a magic bullet and this is not a drug that reduces mortality. We may use it as we don t have a very good antiviral drug. It has a limited role and we should be very careful in its usage, he said.

Randeep guleriaHealth vk paulNational clinical management protocolClinical management protocolsCovid 19Vaccine rolloutOronavirus cases in indiaCoronavirus updatesOrldwide coronavirus casesCovid 19Coronavirus treatmentOvid 19 case tallyOronavirus latest newsCoronavirus pandemicரந்தீப் குலேரியாஆரோக்கியம் வ்க் பால்

Remdesivir not magic bullet, does not reduce mortality, say health experts

Remdesivir not magic bullet, does not reduce mortality, say health experts
indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.

Randeep guleriaHealth vk paulNational clinical management protocolClinical management protocolsரந்தீப் குலேரியாஆரோக்கியம் வ்க் பால்தேசிய மருத்துவ மேலாண்மை ப்ரோடொகால்

Explained: What has led to a crippling shortage of Remdesivir used in Covid treatment | India News

NEW DELHI: Amid an unprecedented surge in fresh Covid-19 infections, multiple states, including Maharashtra, Gujarat and Delhi, have flagged a shortage of anti-viral drug Remdesivir. The shortage prompted the government to halt the export of the drug and Remdesivir active pharmaceutical ingredients (APIs) till the Covid spread is contained. As the country witnesses a ferocious resurgence of the virus, so has the demand for this medicine. Here are a few questions answered on the use of Remdesivir for Covid treatment and problems in the supply chain management. How did Remdesivir come into use? Remdesivir is an investigational antiviral drug to fight Sars-Cov 2, the virus that causes Covid-19. The US Food and Drug Administration (FDA) approved Gilead Sciences Inc’s antiviral therapy Remdesivir in October 2020, making it the first drug to obtain formal clearance for treating the coronavirus disease.

United statesBiocon syngeneZydus cadilaMansukh mandaviaGilead sciencesWorld health organizationDrug administrationGilead sciences incJubilant life sciencesSawai man singh medical collegeNational clinical management protocol for covidUs national institutes of healthNational clinical management protocolInjection remdesivirHetero labsZydus cadila healthcare

Remdesivir not for home use, meant for serious patients, says Govt

The Centre onTuesday said doctors should ensure rational and judicious use of anti-viraldrug Remdesivir, underlining it is to be given only to serious COVID-19 patients in hospitals and is not to be used in home settings. At a weekly press conference, NITI Aayog member (Health) Dr V K Paul said, Remdesivir is to be usedonly in those who require hospitalisation and are onoxygen support. That is the precondition. There isno question of its use in the home setting and for mild cases, and it is not to be procured from chemist shops. Remdesivir is listed for use in serious COVID-19 patientsin the Clinical ManagementProtocols for COVID-19 as aninvestigational therapy.

Union health ministryHealth dr vk paulNational clinical management protocolHealth secretariesClinical management protocolsState health secretariesCovid 19Vaccine rolloutOronavirus cases in indiaCoronavirus updatesOrldwide coronavirus casesCovid 19Coronavirus treatmentOvid 19 case tallyOronavirus latest newsCoronavirus pandemic